Status:
COMPLETED
Monoclonal Gammopathy With Clinical Significance in Patients With and Without Haematological Malignancies in Finistère Between 2012 and 2017 (GammaClinik)
Lead Sponsor:
University Hospital, Brest
Conditions:
Gammopathy, Monoclonal
Eligibility:
All Genders
18+ years
Brief Summary
Clinical symptoms associated with monoclonal gammapathy have been primarily studied in hematological malignancy and rarely in MGUS and hemopathy. Indeed, most studies focus on a specific type of clini...
Eligibility Criteria
Inclusion
- ge \> 18 years Patient with monoclonal gammapathy of undetermined significance with clinical involvement associated with gammapathy or a malignant hematology (myeloma, plasmocytoma, Waldenström's disease, chronic lymphocytic leukemia, B lymphoma) with a monoclonal peak responsible for clinical impairment, Diagnosis of either monoclonal peak, haematopathy or clinical involvement between 2012 and 2017 Obtaining the non opposition
- NB: Clinical Impairment:
- Amylose AL
- cryoglobulinemia
- acquired inhibitor C1 deficiency
- Acquired Willebrand disease;
- bullous dermatosis
- xanthomatosis and xanthogranulomatosis neccrobiotic
- Cold agglutinin disease;
- peripheral neuropathy (anti MAG neuropathy, anti ganglioside, CANOMAD)
- hemolytic uremic syndrome and PTT
- anomaly alternate route of complement
- POEMS syndrome
- Capillary leak and clarkson syndrome
- TEMPI syndrome
- neutrophilic dermatosis: sweet syndrome, sneddon and wilkinson corneal pustulosis, erythema elvatum diutinum, pyoderma gangrenosum
- cutis laxa acquis
- mucinopapulosis
- Schnitzler
- myopathy (Sporadic Late Onset Nemaline Myopathy)
- idiopathic thrombocytopenic purpura
- autoimmune hemolytic anemia
- hyperparathyroidia
- amyotrophic lateral sclerosis
- myasthenia
- Overload crystalline histiocytosis
- Crystalline keratopathy
- GOMMID (monoclonal immunoglobulin microtubular organized deposition glomerulonephritis)
- immunotactoid glomerulopathy
- fanconi syndrome
- randall disease
- PGNMID (Monoclonal immunoglobulin light-chain non-Organic glomerulonephritis)
- Glomerular basal anti-membrane disease
- Extramembranous glomerulonephritis
- glomerulonephritis with C3 deposition
Exclusion
- Clinical involvement due to another condition of the patient (diabetes, hypertension, etc.) Clinical involvement due to chemotherapy Clinical involvement due to a strong tumor mass (IgM cutaneous deposition in Waldenström, cylindrical myeloma nephropathy, hyperviscosity syndrome in Waldenström) Refusal to participate
Key Trial Info
Start Date :
October 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 30 2023
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT06559579
Start Date
October 1 2021
End Date
October 30 2023
Last Update
August 19 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Brest
Brest, France, 29609
2
CHIC de Quimper
Quimper, France